William P. Harris

Oncology

1959 NE Pacific St
Seattle, WA 98195

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Ex vivo tumor derived organoid pharmacotyping identifies personalized therapeutic options for biliary tract cancer patients.

Ex vivo tumor derived organoid pharmacotyping identifies personalized therapeutic options for biliary tract cancer patients.

Journal: Cancer research communications

Published: February 12, 2026

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

Journal: Investigational new drugs

Published: January 29, 2026

Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry.

Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 16, 2026

Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.

Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.

Journal: Cancers

Published: January 03, 2026

Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Journal: JCO oncology practice

Published: December 15, 2025

Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 10, 2025

Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma.

Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: September 02, 2025

Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers.

Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers.

Journal: Cancers

Published: March 16, 2025

A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: March 14, 2025

Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study.

Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study.

Journal: Therapeutic advances in medical oncology

Published: August 06, 2024

Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study.

Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study.

Journal: The oncologist

Published: December 04, 2023

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.

Journal: The oncologist

Published: August 06, 2023

Showing 1-12 of 47

Last Updated: 09/26/2026